JPRN-UMIN000016793
Recruiting
未知
A Pilot Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells in Patients With advanced Renal Cell Carcinoma - A Pilot Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells in Patients With advanced Renal Cell Carcinoma
Tokyo Women's Medical University0 sites10 target enrollmentMarch 13, 2015
Conditionsadvanced Renal cell carcinoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- advanced Renal cell carcinoma
- Sponsor
- Tokyo Women's Medical University
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •No C\-reactive protein with an infectious disease that requires medication, No active infection with hepatitis virus or HIV, No poorly controlled DM or heart failure or arrhythmia, No autoimmune disease and interstitial pneumonia, No other malignancy, No bone of organ transplant recipient, Not pregnant nor nursing, No mental disorder in spite of standard therapy 3\) Other patients judged to be ineligible by the attending investigators were also excluded from the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase II Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells, Teceleukin, and Zoledronic acid in Patients With Stage IV Renal Cell CarcinomaCytokine refractory Renal cell carcinomaJPRN-UMIN000004482Tokyo Women's Medical University35
Completed
Not Applicable
Phase I/IIa Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells in Patients With PSA biochemical failure after radical prostatectomy.JPRN-UMIN000006617Tokyo Women's Medical University10
Unknown
Phase 1
Phase I/II study of adoptive immunotherapy using cytotoxic T cells specific for minor histocompatibility antigen restricted to hematopoietic cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantatio1) RAEB, CMML 2) AML or ALL in induction failure or beyond first remission 3) Ph/p190-positive ALL at any stage 4) imatinib-resistant CMJPRN-C000000162Aichi Cancer Center30
Not yet recruiting
Not Applicable
An exploratory clinical trial of immunotherapy before surgery in stomach cancer casestage I-III stomach cancerJPRN-UMIN000002919JIKEI UNIVERSITY SCHOOL OF MEDICINE50
Completed
Phase 1
A phase 1 study of adoptive immunotherapy using autologous RNF43 peptide pulse dendritic cells and RNF43 peptide specifically activated lymphocytes in patients with advanced solid tumorsadvanced solid tumors which already have finished available standard therapies.JPRN-UMIN000003945Kyushu University Hospital10